Ovesterin (Estriol)

Estriol exerts its effect by binding to estrogen receptors in the vaginal epithelium, stimulating cellular proliferation, glycogen production, and increased blood flow. These actions thicken the mucosal lining, enhance natural lubrication, and normalize vaginal pH, thereby reversing atrophic changes that occur after menopause. The localized mechanism limits systemic exposure while delivering therapeutic benefit where needed.

The appropriate dose of Ovesterin is determined by the prescribing clinician based on the individual patient's condition, severity of symptoms, and response to therapy. Dosage regimens may vary, and patients should follow the specific instructions provided by their healthcare provider. No standardized dosing schedule is provided here.

Safety of estriol-containing products such as Ovesterin has not been established for use in pregnancy or while breastfeeding. Consequently, it is generally not recommended for women who are pregnant, planning to become pregnant, or nursing. Clinicians should evaluate the risk‑benefit profile before prescribing to women of childbearing potential.

To order Ovesterin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Ovesterin delivers estriol, a weaker estrogen compared with estradiol‑based products. This lower potency often results in fewer systemic estrogenic effects, making it suitable for localized vaginal therapy. While estradiol may provide stronger systemic symptom relief, estriol’s weaker activity can be advantageous for patients who require minimal systemic exposure or who have contraindications to higher‑potency estrogens.

Ovesterin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use. Do not freeze or expose the medication to extreme temperatures.

Ovesterin is administered intravaginally. The prescribed tablet or applicator is inserted into the vagina according to the healthcare provider’s instructions, typically using a clean fingertip or applicator device. Patients should follow the dosing schedule advised by their clinician and maintain proper hygiene before and after insertion.

Serious risks include allergic reactions such as rash, swelling, or anaphylaxis; endometrial hyperplasia leading to abnormal uterine bleeding; unexpected vaginal bleeding; thromboembolic events like deep‑vein thrombosis or pulmonary embolism; and significant breast tenderness or enlargement. Patients should seek immediate medical attention if any of these symptoms occur.

Ovesterin is contraindicated in individuals with a known history of estrogen‑dependent cancers (e.g., breast or endometrial cancer), active or past thromboembolic disease, uncontrolled hypertension, severe liver disease, or known hypersensitivity to estriol or any excipients in the formulation. Pregnant or potentially pregnant women should also avoid using this product.